TROPiCS-02 Trial Sees Progression-Free Survival Edge for Trodelvy-Treated Advanced Breast Cancers

The antibody-drug conjugate stretched out time to progression in a Phase III trial of pretreated patients with advanced hormone receptor-positive, HER2-negative breast cancers.

Related Keywords

California ,United States ,Foster City ,San Francisco ,American ,Jane Lowe Meisel ,Veronique Dieras ,University Of California ,Eugene Marquis Center ,American Society Of Clinical Oncology ,Emory University ,Drug Administration ,Gilead Sciences Antibody Drug ,American Society ,Clinical Oncology ,Hope Rugo ,Helen Diller Family Comprehensive Cancer Center ,Lowe Meisel ,